The rabbit study: Ritonavir and saquinavir in combination in saquinavir- experienced and previously untreated patients

AIDS Research and Human Retroviruses

Volumn 15, Issue 13, 1999, Pages 1181-1189

  Churchill, Duncan R ^a,h   Pym, Alexander S ^a   Galpin, Sarah ^a   Foxall, Russell ^a   Stainsby, Chris ^a   Clarke, John R ^a   Kaye, Steve ^b   Bloor, Stuart ^c   Larder, Brendan A ^c   Wills, Ben ^d   Sun, Eugene ^e   Babiker, Abdel G ^f   Back, David J ^g   Weber, Jonathan N ^a  

^a IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^c Virco UK Ltd   (United Kingdom)

^d ROCHE PRODUCTS LTD   (United Kingdom)

^e ABBOTT LABORATORIES   (United States)

^f MEDICAL RESEARCH COUNCIL   (United Kingdom)

^g UNIVERSITY OF LIVERPOOL   (United Kingdom)

^h ROYAL SUSSEX COUNTY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

RITONAVIR; SAQUINAVIR; ZALCITABINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CROSS RESISTANCE; DIARRHEA; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; MALE; NAUSEA; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHENOTYPE; POINT MUTATION; PREDICTION; PRIORITY JOURNAL; PROTEINASE INHIBITION; VIRUS LOAD; VOMITING;

EID: 0033200240     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/088922299310278     Document Type: Article

References (34)

1. Mouton Y, Alfandari S, Valette M, et al.: Impact of protease inhibitors on AIDS-defining events and hospitalizations in 10 French AIDS reference centres. AIDS 1997;11:F101-F105.
2. Torres RA and Barr M: Impact of combination therapy for HIV infection on inpatient census. N Engl J Med 1997;336:1531-1532.
3. Hogg RS, O'Shaughnessy MV, Gataric N, et al.: Decline in deaths from AIDS due to new antiretrovirals. Lancet 1997;349:1294.
4. Anonymous: AIDS deaths fell by 44%, but over 2500 HIV infections were reported in 1997. Communicable Disease Report (CDR Rev) 1998;8:29.
5. Palella FJ, Delaney KM, Moorman AC, et al.: Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998;338:853-860.
6. Conant M, Opp KM, Poretz D, and Mills RG: Reduction of Kaposi's sarcoma lesions following treatment of AIDS with ritonavir. AIDS 1997;11:1300-1301.
7. Carr A, Marriott D, Field A, Vasak E, and Cooper DA: Treatment of HIV-1-associated microsporidiosis and cryptosporidiosis with combination antiretroviral therapy. Lancet 1998;351:256-261.
8. Sepkowitz K: Effect of HAART on natural history of AIDS-related opportunistic disorders. Lancet 1998;351:228-230.
9. Gulick RM, Mellors JW, Havlir D, et al.: Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997;337:734-739.
10. Hammer SM, Squires KM, Hughes MD, et al.: A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 1997;337:725-733.
11. Deeks S, Loftus R, Cohen P, Chin S, and Grant R: Incidence and predictors of virologic failure to indinavir (IDV) or/and ritonavir (RTV) in an urban health clinic. In 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Ontario, Canada, 1997. [Abstract LB-2]
12. Fatkenheuer G, Theisen A, Rockstroh J, et al.: Virological treatment failure of protease inhibitor therapy in an unselected cohort of HIV-infected patients. AIDS 1997;11:F113-F116.
13. Roberts NA: Drug-resistance patterns of saquinavir and other HIV proteinase inhibitors. AIDS 1995;9(Suppl. 2):S27-S32.
14. Boucher C: Rational approaches to resistance: Using saquinavir. AIDS 1996;10(Suppl. 1):S15-S19.
15. Eberle J, Bechowsky B, Rose D, et al.: Resistance of HIV type 1 to proteinase inhibitor Ro 31-8959. AIDS Res Hum Retroviruses 1995;11:671-676.
16. Jacobsen H, Yasargil K, Winslow DL, et al.: Characterization of human immunodeficiency virus type 1 mutants with decreased sensitivity to proteinase inhibitor Ro 31-8959. Virology 1995;206: 527-534.
17. Ives KJ, Jacobsen H, Galpin SA, et al.: Emergence of resistant variants of HIV in vivo during immunotherapy with the proteinase inhibitor saquinavir. J Antimicrob Chemother 1997;39:771-779.
18. Roberts NA, Craig JC, and Sheldon J: Resistance and cross-resistance with saquinavir and other HIV protease inhibitors: Theory and practice. AIDS 1998;12:453-460.
19. Hsu A, Granneman GR, Sun E, et al.: Assessment of single and multiple-dose interactions between ritonavir and saquinavir. In XIth International Conference on AIDS, Vancouver, 1996. [Abstract LB.B.6041]
20. Merry C, Barry MG, Mulcahy F, et al.: Saquinavir pharmacokinetics alone and in combination with ritonavir in HIV-infected patients. AIDS 1997;11:F29-F33.
21. Cameron W, Sun E, Markowitz M, et al.: Combination use of ritonavir and saquinavir in HIV-infected patients: Preliminary safety and activity data. In XIth International Conference on AIDS, Vancouver, 1996. [Abstract Th.B.934]
22. Cameron DW, Japour A, Mellors J, et al.: Antiretroviral safety and durability of ritonavir (RIT)-saquinavir (SQV) in protease inhibitor-naive patients in year two follow-up. In 5th Conference on Retroviruses and Opportunistic Infections. Chicago, 1998. [Abstract 388]
23. Kitchen VS, Skinner C, Ariyoshi K, et al.: Safety and activity of saquinavir in HIV infection. Lancet 1995;345:952-955.
24. Pym AS, Churchill DR, Galpin S, et al.: Sustained benefit after four years of saquinavir monotherapy. In XIth International Conference on AIDS, Vancouver, 1996. [Abstract Tu.B.2123]
25. Kaye S, Loveday C, and Tedder RS: A microtitre format point mutation assay: application to the detection of drug resistance in human immunodeficiency virus type-1 infected patients treated with zidovudine. J Med Virol 1992;37:241-246.
26. Hertogs K, de Bethune MP, Miller V, et al.: A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs. Antimicrob Agents Chemother 1998;42:269-276.
27. Larder BA and Kemp SD: Multiple mutations in HIV-1 reverse transcriptase confer high level resistance to zidovudine. Science 1989;246:1155-1158.
28. Larder BA, Kohli A, Kellam P, Kemp SD, Kronick M, and Henfrey RD: Quantitative detection of HIV-1 drug resistance mutations by automated DNA sequencing. Nature (London) 1993;365: 671-673.
29. Kitchen V, on behalf of the Quattro Steering Committee: A randomised trial comparing regimens of four RT inhibitors given together or cyclically with a standard two drug regimen: The Quattro trial. In 5th Conference on Retroviruses and Opportunistic infections, Chicago, 1998. [Abstract 701]
30. Barry M, Gibbons S, Back D, and Mulcahy F: Protease inhibitors in patients with HIV disease. Clinically important pharmacokinetic considerations. Clin Pharmacokinet 1997;32:194-209.
31. Noble S and Faulds D: Saquinavir: A review of its pharmacology and clinical potential in the management of HIV infection. Drugs 1996;52:93-112.
32. Lloyd J, Carey P, Timmins D, et al.: Trough plasma saquinavir levels in HIV-positive patients. In 6th European Conference on Clinical Aspects and Treatment of HIV Infection, Hamburg, 1997. [Abstract 461]
33. Winters MA, Schapiro JM, Lawrence J, and Merigan TC: Human immunodeficiency virus type 1 protease genotypes and in vitro protease inhibitor susceptibilities of isolates from individuals who were switched to other protease inhibitors after long-term saquinavir treatment. J Virol 1998;72:5303-5306.
34. Molla A, Korneyeva M, Gao Q, et al.: Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nature Med 1996;2:760-766.